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ABSTRACT It is not currently possible to predict the probability of whether a woman with a chlamydial genital infection will de-
velop pelvic inflammatory disease (PID). To determine if specific biomarkers may be associated with distinct chlamydial patho-
types, we utilized two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) that differ in their
abilities to elicit upper genital tract pathology in a mouse model. CmVar004 has a lower growth rate in vitro and induces pathol-
ogy in only 20% of C57BL/6 mouse oviducts versus 83.3% of oviducts in CmVar001-infected mice. To determine if chemokine
and cytokine production within 24 h of infection is associated with the outcome of pathology, levels of 15 chemokines and cyto-
kines were measured. CmVar004 infection induced significantly lower levels of CXCL1, CXCL2, tumor necrosis factor alpha
(TNF-), and CCL2 in comparison to CmVar001 infection with similar rRNA (rs16) levels for Chlamydiae. A combination of
microRNA (miRNA) sequencing and quantitative real-time PCR (qRT-PCR) analysis of 134 inflammation-related miRNAs was
performed 24 h postinfection to determine if the chemokine/cytokine responses would also be reflected in miRNA expression
profiles. Interestingly, 12 miRNAs (miR-135a-5p, miR298-5p, miR142-3p, miR223-3p, miR299a-3p, miR147-3p, miR105,
miR325-3p, miR132-3p, miR142-5p, miR155-5p, andmiR-410-3p) were overexpressed during CmVar004 infection compared to
CmVar001 infection, inversely correlating with the respective chemokine/cytokine responses. To our knowledge, this is the first
report demonstrating that early biomarkers elicited in the host can differentiate between two pathological variants of chlamyd-
iae and be predictive of upper tract disease.
IMPORTANCE It is apparent that an infecting chlamydial population consists of multiple genetic variants with differing capabili-
ties of eliciting a pathological response; thus, it may be possible to identify biomarkers specific for a given virulence pathotype.
miRNAs are known to regulate genes that in turn regulate signaling pathways involved in disease pathogenesis. Importantly,
miRNAs are stable and can reflect a tissue response and therefore have the potential to be biomarkers of disease severity. Cur-
rently, with respect to chlamydial infections, there is no way to predict whether an infected patient is more or less likely to de-
velop PID. However, data presented in this study indicate that the expression of a specific miRNA profile associated with a viru-
lent variant early in the infection course may be predictive of an increased risk of pelvic inflammatory disease, allowing more
aggressive treatment before significant pathology develops.
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Chlamydia trachomatis infections in women differ greatly in thenature and intensity of disease. A major conundrum with re-
spect to chlamydial infections iswhy somewomendevelop clinical
disease while the majority remain asymptomatic. Clearly, there
can bemultiple reasons for this, including host genetic differences
(1), the use of oral contraceptives (2, 3), the stage of themenstrual
cycle in which infection occurs (4), and the presence of other risk
factors such as bacterial vaginosis (5), but it is more likely that a
combination of factors is responsible. Another possible explana-
tion is that the infecting population consists of multiple genetic
variants, with the pathological phenotype being dependent upon
the numerical representation of variants in the infecting popula-
tion. Miyairi and colleagues recognized differences among sero-
vars of C. trachomatis, reporting that ocular serovars had longer
developmental cycles and lower growth rates than genital sero-
vars, and related this to the pathotype (6). Along the same line,
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Kari et al. tested two different isolates of C. trachomatis serovar A
and observed that one isolate which had smaller plaques, slower
growth, and increased sensitivity to gamma interferon (IFN-)
had a lower peak number of organisms with shorter infection and
lesser pathology upon conjunctival infection of nonhuman pri-
mates (7). Thus, it is clear that even within a given serovar, there
can be significant variations in virulence.
The concept that variants within populations exist naturally
was presented by Ramsey and colleagues in their examination of
the Nigg and Weiss strains of C. muridarum which differ in viru-
lence (8).We reported a similar observation using plaque-purified
C. caviae isolated from a conjunctival swab from an infected
guinea pig (9). In an elegant study, Sturdevant and colleagues
infected mice with C. trachomatis serovar D and found that mice
resolved infections at vastly different times, from 10 to 77 days
(10). They found that when mice were infected with chlamydiae
isolated frommice at 10 days and 49 days postinfection, the infec-
tion courses were consistently shorter for the day 10 isolate and
longer for the day 49 isolate. Moreover, the day 49 isolate pro-
duced more pathology in the upper genital tract than the day 10
isolate. The authors concluded that the “serovar D parental stock
was a mixture of organisms varying in virulence for the mouse”
(10). The study results clearly indicate that infecting populations
consist of mixtures of variants with different pathological capabil-
ities and that the outcome of the infection is dependent upon the
virulence of those variants within the population.
Currently, there is no way to determine whether a woman in-
fected with Chlamydia is at risk for upper genital tract disease. It
would be advantageous if one could identify specific biomarkers
that would help to predict the pathological outcome of the infec-
tion early in the disease process to enable proactive treatment for
the prevention of pelvic inflammatory disease (PID). MicroRNAs
(miRNAs) are abundant and evolutionarily conserved noncoding
small (~22-nucleotide) oligonucleotide molecules. They are im-
mune modulators that serve as an important link between innate
and adaptive immune responses (11). Dysregulation of miRNA
expression has been linked to cardiovascular diseases, cancer, in-
fectious metabolic diseases, and other diseases (12–14). Most im-
portantly, miRNAs have been shown to regulate chemokine cyto-
kine responses during different bacterial infections (15, 16). In
addition, several studies have suggested that miRNAs could be a
new class of biomarkers for diagnostic and therapeutic purposes
under different pathological conditions (17, 18). Thus, we hy-
pothesized that different pathological variants of C. muridarum
would elicit differentmiRNAprofiles and that such profiles would
be predictive of the development or lack of development of upper
genital tract disease. In this study, we characterized two chlamyd-
ial variants (C. muridarum Var001 [CmVar001] and CmVar004)
that differ in their abilities to induce upper genital tract pathology
in mice by examining microRNA (miRNA) expression profiles
induced by these variants and their relationship to chemokine/
cytokine responses within 24 h of infection.
RESULTS
In vitro growth characteristics of chlamydial variants.We char-
acterized plaque-purified variants of C. muridarum derived from
genital tract swabs of infectedmice. These variants differed in their
plaque size and in vitro growth characteristics (Table 1). Growth
curve analysis of variants showed different phenotypes, with
CmVar001 being the fastest growing variant followed by
CmVar002, while CmVar001.1, CmVar003, and CmVar004 had
lower growth rates. The rate of elementary body (EB) generation
per developmental cycle was calculated by dividing the number of
infectious progeny from supernatants at 36 h by the number of
EBs used to infect the cultures (multiplicity of infection  1).
Similarly, the EB generation rate was higher for CmVar001 and
CmVar002 than forCmVar001.1, CmVar003, andCmVar004. In-
terestingly, there was a 6-fold difference in EB production rates
betweenCmVar001 andCmVar004, and the doubling time results
showed that the 2-fold EB increase time for CmVar004 was
136 min versus 78 min for CmVar001, indicating that, in vitro,
CmVar004 grows slower than CmVar001. While, with the excep-
tion of the plaque size, the data were not evaluated statistically, as
only two growth curve experiments were performed, nevertheless,
the data do suggest phenotypic differences among the variants.
In vivo disease phenotype of infection with chlamydial vari-
ants. Since the above data demonstrated that the variants have
different growth phenotypes in vitro, it was important to deter-
minewhether theywould also differ in vivo in a genital infection of
mice. C57BL/6 and BALB/c mice were infected genitally with 3
105 inclusion-forming units (IFU), and the course of the infection
was monitored by measuring the number of IFU in genital tract
swabs. No statistical significant differences in the bacterial loads
were noted during the primary course of infection in C57BL/6
mice infected with C. muridarum variants CmVar001 and
CmVar004 (2-factor [day, group] analysis of variance with re-
peated measures), but a longer infection was observed in mice
infected with CmVar001 (see Fig. S1A in the supplemental mate-
rial). In contrast, CmVar001 elicited a significantly higher bacte-
rial burden and longer infection in BALB/c mice than in mice
infected with CmVar004 (P  0.0001) (see Fig. S1B). Further-
more, there were no statistical significant differences between the
results determined for mice infected with CmVar001.1,
CmVar002, or CmVar003 and those determined formice infected
with CmVar004 or CmVar001.
An important measure of disease outcome is the development
of hydrosalpinx, which is associated with infertility. Hence; we
assessed the presence of hydrosalpinx 35 days after infection in







Rate of 2-fold EB
increase (min)
CmVar001 1.05 0.29 25.4 3.8 78
CmVar001.1 0.96 0.08 14.4 3.1 121
CmVar002 0.97 0.25 22.3 1.4 87
CmVar003 0.38 0.25* 8.8 0.7 128
CmVar004 0.55 0.16* 3.8 2.2 136
a *, P 0.00001 according to a two-tailed t test compared to CmVar001.
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each of two groups of five C57BL/6 mice infected with one of the
variants (Table 2). Because of major differences in hydrosalpinx
development in mice infected with CmVar001 versus those in-
fected with CmVar004, the experiment with those groups was
repeated twice. Importantly, there was a significant difference
with respect to the development of hydrosalpinx between mice
infected with the CmVar001 and CmVar004 variants (chi-square
test with Yates correction, P  0.0001), with only 4 of 15 mice
infected with CmVar004 developing unilateral or bilateral hydro-
salpinx compared to 14 of 15 mice infected with CmVar001. Sim-
ilarly, 6 of 30 (20%) oviducts in CmVar004-infected mice were
positive for hydrosalpinx in contrast to 25 of 30 (83.3%) oviducts
in mice infected with CmVar001. A similar difference was ob-
served in BALB/c mice. Mice infected with the CmVar001.1,
CmVar003, and CmVar002 variants showed an intermediate phe-
notype with regard to the production of hydrosalpinx, although
all of the results were statistically significantly different from those
determined for the mice infected with CmVar001 (chi-square test
with Yates correction, P  0.01). In addition, CmVar001 also
elicited significantly more hydrosalpinx formation than did the
original C. muridarum parent stock from which the variants were
derived (chi-square test with Yates correction, P  0.007) (Ta-
ble 2).
The significant difference in the development of upper genital
tract disease raised the issue of whether CmVar001 and
CmVar004 were reaching the upper tract at the same rate. There-
fore, C57BL/6 mice were infected intravaginally, and on day 10,
oviducts and the upper portion of the uterine horns were pro-
cessed for the isolation and enumeration of chlamydiae. Similar
numbers of chlamydiae were found in the oviducts and upper
uterine horns of CmVar001- and CmVar004-infected mice, sug-
gesting that the bacterial load is not the cause of the reduced pa-
thology observed in CmVar004-infected mice (Fig. 1). We ob-
served that 9 animals gave positive CmVar004 results in upper
tract isolations and that all 10 animals gave positive CmVar001
results in the upper genital tract. We chose to use only CmVar001
and CmVar004 for further experiments because they represented
the opposite extremes in growth rates and pathology induction of
the variants.
Differential expression of chemokines and cytokines during
chlamydial infection. Production of specific chemokines and cy-
tokines is inherent in the development of a pathological response
to chlamydial infection. Because there were differences in the
courses of infection and the development of pathology during
CmVar001 and CmVar004 infection, we expected to observe a
difference in the chemokine and cytokine profiles elicited by each
variant. To evaluate the chemokine and cytokine profile in the
cervix, we analyzed cervical tissue at 24 h postinfection for the
expression of 15 key chemokines and cytokines (tumor necrosis
factor alpha [TNF-], interleukin-1 [IL-1], IL-6, IL-10,
CXCL10, CXCL1, CXCL2, CCL1, CCL2, CCL3, CCL4, CCL5,
IFN-, IFN-, and transforming growth factor [TGF-]) which
we previously showed to be upregulated 24 h after chlamydial
infection (19). C57BL/6 mice were infected intracervically rather
than intravaginally since intracervical inoculation places a large
number of chlamydiae directly at the target tissue and results in a
synchronous infection for the first developmental cycle (~42 to
~48 h). We performed an initial screen and determined that ani-
mals infectedwith CmVar001 andCmVar004 had similar levels of
chlamydial rRNA (rs16) (data not shown) 24 h postinfection. We
observed significantly lower levels of CXCL1, CXCL2, TNF-,
CCL1, and CCL2 in cervical tissue from mice infected with Cm-
Var004 than in cervical tissue frommice infected with CmVar001
(Fig. 2A) (P  0.05 according to a one-tailed t test). A trend to-
ward decreased expression of IL-1, CXCL10, and IL-6 was also
TABLE 2 In vivo phenotype of chlamydial variantsa
C. muridarum
variant
No. of mice positive for hydrosalpinx/total no. of mice (%) No. of oviducts positive for hydrosalpinx/total no. of oviducts (%)
C57BL/6 BALB/c C57BL/6 BALB/c
CmVar001 14/15 (93.3) 5/5 (100) 25/30 (83.3) 10/10 (100)
CmVar001.1 3/5 (60) 3/10 (30)†
CmVar002 4/5 (80) 4/10 (40)**
CmVar003 4/5 (80) 4/10 (40)**
CmVar004 4/15 (26.7)† 6/30 (20)# 5/10 (50)*
Parent stock 5/8 (62.5) 7/16 (44)†
a P values compared to CmVar001 using the chi-square test with the Yates correction (one tailed) in comparison to CmVar001 are indicated as follows: *, P 0.05; **, P 0.02;
†, P 0.008; #, P 0.0001.
FIG 1 Upper genital tract isolations of CmVar001 and CmVar004 variants
indicate similar numbers of IFU in oviducts and upper uterine horns. C57BL/6
micewere infected at 3 105 IFU, and cervical swabswere collected once every
3 days to determine the IFU on aMcCoy cell monolayer. On day 10, mice were
euthanized to collect oviducts and samples of an upper portion of uterine horn
and of tissue were homogenized, sonicated, and plated on HeLa cell monolay-
ers for determination of IFU. Log10 IFU/ml values were calculated from genital
swabs and tissue isolations, and the averages of the results determined for 10
animals were plotted as means standard deviations. The numbers above the
bars indicate the ratios of the number ofmice positive for unilateral or bilateral
hydrosalpinx to the total number of mice. Cervical swab data indicated that all
mice were infected in the lower genital tract (data not shown). No statistical
significant differences between CmVar001 and CmVar004 upper tract isola-
tions were observed by a two-way analysis of variance (ANOVA).
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observed with CmVar004 infection, though it was not statistically
significant (data not shown). In addition, the other chemokines
and cytokines measured were similarly expressed in CmVar001
and CmVar004 (data not shown). These data indicated that Cm-
Var004 induced lower levels of important molecules for the initi-
ation of the inflammatory response (TNF-, CXCL1, CXCL2)
than CmVar001, correlating with the relative pathogenicities of
each variant.
Since it is likely that these molecules are produced by the in-
fection of epithelial cells, we wanted to determine if we would see
a similar phenomenon in vitro in the infection of mouse genital
tract epithelial cells. Mouse oviduct epithelial cells (Bm1.11) were
infected with CmVar001 and CmVar004 variants at a multiplicity
of infection of 1. At 24 h postinfection, RNA was isolated and
expression levels of various chemokines and cytokines were deter-
mined. The data strongly supported the in vivo results, in that
CmVar004 induced significantly lower levels of CXCL1, CXCL2,
TNF-, and CCL2 with similar levels of rs16 than did CmVar001
(Fig. 2B) (P  0.05). Therefore, both the in vitro and in vivo
chemokine and cytokine expression data correlatedwith the path-
ological outcomes of the attenuated CmVar004 and the virulent
CmVar001 variants. These data indicate that the early chemokine
and cytokine responses elicited in mice within the first develop-
mental cycle of chlamydial infection by defined virulent and at-
tenuated variants are predictive of the outcome of the disease,
resulting in more and less upper tract pathology, respectively.
Differential expression of miRNA(s) during chlamydial in-
fection. In mammalian cells, miRNAs play a pivotal role in regu-
lation of different processes such as development, metabolism,
and inflammation as well as in modulating chemokine and cyto-
kine expression (15, 21–26). However, the role inflammation-
related miRNAs play during chlamydial pathogenesis and their
correlation to chemokine and cytokine expression has not been
studied. The population of miRNAs elicited by CmVar001,
CmVar004, and sham inoculation of control mice (4 C57BL/6
mice for each group) infected by the intracervical route was first
explored by relatively low-coverage Illumina MiSeq sequencing.
This small-RNA sequencing and bioinformatic analysis identified
2,935 uniquely mapped mouse miRNAs (data not shown). Using
stringent cutoff values, differential expression analysis comparing
the CmVar001- and CmVar004-infected mice to the sham-
inoculated mice identified five (CmVar004 versus controls) and
FIG 2 Chemokine and cytokine expression analyses from mice and BM1.11 cells. C57BL/6 mice were infected with 1 107 IFU of CmVar001 or CmVar004
variants by intracervical inoculation. (A) Expression levels of chemokine and cytokine transcripts are plotted as fold change relative to control levels, and only
CmVar001 andCmVar004 gene results that were statistically significantly different are shown in the graph.Data are froman average of 9 animals per groupwhere
CmVar004 infection had lower expression of CXCL1, CXCL2, TNF-, and CCL1 than CmVar001 infection (*, P  0.05, one-tailed t test). We observed that
CXCL2 results were significant at 10% (**,P 0.09) and that CCL2 results were significant at 6% (**,P 0.06). (B)Mouse oviduct epithelial cells (BM1.11)were
infected with CmVar001 and CmVar004 and variants. The graph is a representation of three individual experiments, and data represent an average of three
samples per each group (*, P 0.01, one-tailed t test). exp, expression.
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four (CmVar001 versus controls) miRNAs that were significantly
differentially expressed (Table 3). Two miRNAs, miR223-3p and
miR18a-5p, were common to CmVar001 and CmVar004. Fur-
ther, differential expression analysis of CmVar001 versus
CmVar004 showed that miR223-3p was overexpressed in
CmVar004-infected mice (Table 3). The relatively low-coverage
small-RNA sequencing analysis results presented above provided
evidence that CmVar001 and CmVar004 elicit different host
miRNA responses.
In order to confirm sequencing results and also focus on the
miRNAs involved in immunopathogenesis, we measured the ex-
pression profile of 134 miRNAs by real-time PCR, at 24 h after
intracervical infection, using 5 C57BL/6 mice per group. We ob-
served differential expression of miRNAs during CmVar001 and
CmVar004 infection in comparison to sham-inoculated control
mice. There were distinct differences in the types and levels of the
miRNAs expressed inmice infected by CmVar001 andCmVar004
compared to controls. Data analyses of miRNA for 1.5-fold or
higher differences between CmVar001 and CmVar004 indicated
that 12 miRNAs were expressed at higher levels with CmVar004
infection than with CmVar001. Among the 12, we observed that
10 miRNAs (miR-135a-5p, miR298-5p, miR142-5p, miR223-3p,
miR147-3p, miR105, miR132-3p, miR142-3p, miR155-5p, and
miR-410-3p) were upregulated inmice infected with the avirulent
CmVar004 variant in comparison to mice infected with the viru-
lent CmVar001 variant (Fig. 3 and Table 4). Two miRNAs,
miR-299a-3p and miR-325-3p, were downregulated in both in-
fections; however, the downregulation was significantly greater in
animals infected with CmVar001. As shown in Table 4,
miR-155-5p,miR-142-3p,miR-132-3p,miR105,miR223-3p, and
TABLE 3 DEseq of miRNAs discovered by sequencinga
Comparison and miRNA MRC Log fold change P value FDR
Control versus CmVar001 CmVar001 Controls
mmu-miR-223-3p 78.00 29.73 1.39 0.0000 0.0003
mmu-miR-203-3p* 430.87 121.22 1.83 0.0000 0.0003
mmu-miR-18a-5p* 22.29 5.64 1.98 0.0000 0.0021
mmu-miR-215-5p 12.51 0.00 0.0000 0.0000
Control vs CmVar004 CmVar004 Controls
mmu-miR-98-5p 137.96 57.49 1.26 0.0000 0.0001
mmu-miR-21a-3p 146.06 56.68 1.37 0.0000 0.0000
mmu-miR-155-5p 34.77 8.91 1.96 0.0000 0.0001
mmu-miR-18a-5p* 23.50 5.41 2.12 0.0000 0.0001
mmu-miR-223-3p* 175.75 28.51 2.62 0.0000 0.0000
CmVar001 versus CmVar004 CmVar001 CmVar004
mmu-miR-223-3p 61.00 100.00 1.00 0.0002 0.04
mmu-miR-203-3p 300.00 100.00 2.00 0.0001 0.02
a MRC, mean read count; FDR, false discovery rate. Cutoff of FDR 0.05; minimum 10 reads; upper fold change 1; *, lower fold change1. DEseq, differential expression
levels.
FIG 3 miRNA expression analyses frommice. C57BL/6 mice were infected with 1 107 IFU of CmVar001 or CmVar004 variants by intracervical inoculation,
and the miRNA expression profile was measured as described in Materials and Methods. Results represent an average of 5 to 7 animals per group; statistical
significance was determined by the Wilcoxon rank sum one-tailed test (Bonferroni correction), with P  0.05 being considered significant. Data analyses of
miRNA for determinations of differences between CmVar004 and CmVar001 results at a level of 1.5-fold or higher indicate that 12 miRNAs were expressed at
higher levels with CmVar004 infection than with CmVar001 infection and that the results for 6 miRNAs were statistically significant as well.
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mir-147-3p regulate chemokine and cytokine responses as well as
modulating Toll-like receptor 2 (TLR2) expression under differ-
ent pathological conditions (15, 21–25). These data indicate that
miRNAs expressed at higher levels during CmVar004 infection
are associated with the downregulation of chemokine and cyto-
kine expression in mice, resulting in lesser upper genital tract pa-
thology during a CmVar004 infection. Conversely, the low ex-
pression level of these inflammatory miRNAs in mice infected
with the virulent CmVar001 variant is associated with the in-
creased incidence of hydrosalpinx in those mice.
Comparative genome sequencing of chlamydial variants.
High-quality draft genomes were obtained for eachC.muridarum
plaque variant by deep sequencing (see Table S1 in the supple-
mentalmaterial). A draft assembly of the conservedC.muridarum
plasmid was also recovered for each plaque variant, excluding the
possibility that the attenuated growth and virulence phenotypes
were caused by plasmid-free C. muridarum (27). Using the pub-
lished C. muridarum Nigg genome (Genbank accession no.
AE002160) as a reference, comparative genome analysis identified
52 high-quality single nucleotide polymorphisms (SNPs) and in-
sertions and deletions (indels), supported by very deep sequence
coverage (2,600), within the draft plaque variant genomes,
including synonymous and nonsynonymous changes, likely re-
sulting in several frameshiftmutations (Table 5; see also Table S2).
The pattern for 18 of these SNPs or indels within or between
predicted genes across the plaque variants correlates with the ob-
served phenotypes of differential growth rates and gross pathology
(Table 5; see also Table S2). Nine of these SNPs and indels occur
within the ompA gene (TC0052) that encodes the major outer
membrane protein (MOMP). These mutations cause an amino
acid deletion within the MOMP third variable domain (VD3) in
the CmVar001 variant (Table 5 and data not shown). In the
CmVar004 variant, these mutations cause a double amino acid
deletion and a glycine-to-cysteine substitution within MOMP
VD4 (Table 5 and data not shown). The glycine-to-cysteine sub-
stitution may impact MOMP structure and intramolecular com-
plexing through disulfide cross-linking (28, 29). Phenotype-
correlating mutations across plaque variants are observed in
several other genes, including TC0412 (homolog of CT135),
TC0155 [3=(2=),5=-bisphosphate nucleotidase], and TC0682 (tet-
raacyldisaccharide 4=-kinase) (Table 5; see also Table S2).
Phenotype-correlating mutations are also found within several
genes with no known function (annotated as conserved hypothet-
ical genes); this suggests that these genes may have functions that
are related to the observed variant phenotypes. Notably, disrup-
tion of CT135 was recently shown to reduce infectivity in a C. tra-
chomatis mouse model of infection (30). Thus, comparative
genomic analysis of plaque-purified variants identified mutations
that may explain the virulence characteristics of variants in a par-
ticular stock.
DISCUSSION
Chlamydial genital infections, as in many infectious diseases, vary
greatly in the clinical outcome of the disease, ranging from sub-
clinical infection with little or no sequelae to full-blown cervicitis
followed by pelvic inflammatory disease resulting in tubal ob-
struction, ectopic pregnancy, or infertility. Using the C. muri-
darummouse model of genital infection, we undertook studies to
expand upon the concept that a given chlamydial population con-
sists of variants with different levels of pathogenic potential. In
support of this concept, 5 plaque-purified isolates from mice in-
fected with the less virulent Nigg strain were characterized for
their pathology-inducing capabilities. Interestingly, even though
the choosing of the plaques for evaluation was purely random, a
range of pathology-associated phenotypes was identified. While
there was little difference in the infection courses, two variants,
CmVar001 and CmVar004, differed dramatically in the ability to
elicit hydrosalpinx. This ability was reflected in their plaque size,
growth rate, and chemokine profile, with the more virulent vari-
ant having an increased growth rate and increased production of
proinflammatory chemokines.
Deep genome sequencing of these variants identified patterns
of mutations that correlated with these observed growth and vir-
ulence phenotypes, but no definitive conclusions can be drawn
linking a specificmutation to the virulence phenotype. Thus, even
though the initial infection population of chlamydiae was rela-
tively attenuated, variants were present in that population with a
wide range of pathogenic potential. It is interesting that a virulent
variant was contained in the parent population but that virulence
was not reflected in the overall pathological phenotype of the par-
ent population. Whether the pathogenicity of a given population
represents the sum total or the average of the pathogenicities of its
constituent variants cannot be concluded at this point. What is
clear is that the virulence phenotype of a population does not










miR-135a-5p 1.55 0.003 ND
miR-299a-3p 1.63 0.05 ND
miR-155-5p 1.64 N.S. CXCL12 (15)
miR-142-3p 1.75 N.S. IRAK1 (23)
miR-132-3p 1.76 N.S. IRAK42, TNF- (50)
miR-325-3p 1.81 N.S. ND
miR-105 1.83 N.S. TLR22, TNF-, IL-6 (21)
miR-410-3p 1.86 N.S. ND
miR-223-3p 2.04 0.05 IL-1B2, IL-62, TNF- (22)
miR-298-5p 2.10 0.02 ND
miR-142-5p 2.23 0.02 ND
miR-147-3p 4.54 0.05 TLR22, TNF-, IL-6 (24)
a N.S., not significant; ND, not determined.
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necessarily reflect the virulence phenotype of all of the individual
variants within that population. Using C. caviae in the guinea pig
model of chlamydial genital infection,we previously observed that
when a wild-type variant, capable of eliciting a strong inflamma-
tory response, and a less virulent and slower-growing variant elic-
iting significantly less inflammation are inoculated together into
the animal, the outcome of the infection resembles that of the
virulent variant (31). Moreover, even though equal numbers of
the variants are inoculated, the wild-type variant becomes domi-
nant by the end of the infection (31). This suggested that the com-
position of a chlamydial population is dynamic and constantly in
flux, governed by host genetics and microenvironment of the in-
fection site, among other factors.
If the composition of individual variants within a chlamydial
population defines the potential pathological outcome of the dis-
ease, the identification of specific variants associated with more-
severe disease might aid in determining the risk of upper tract
disease. However, while it is technically feasible to genotype a
chlamydial population from a swab (32–34), it is not yet logisti-
cally and economically feasible to use this methodology in a clinic
setting. Moreover, we are still a long way from being able to de-
finitively state which gene or group of genes determines chlamyd-
ial virulence capability. It is currently more practical to determine
if there is a particular host factor(s) that demonstrates the poten-
tial for more-severe disease, particularly a more intense acute in-
flammatory response. The number of polymorphonuclear leuko-
cytes (PMNs) present in a cervical scraping is an inexact measure
and has been of limited diagnostic use for PID. Nevertheless, it is
interesting that the virulent CmVar001 variant results in the ex-
pression of significantly greater levels of key inflammatory cyto-
kines and chemokines, including TNF-, CXCL1, CXCL2, and
CCL1, than the attenuated CmVar004 variant both in vitro and in
vivo. Importantly, these differences were noted at 24 h after infec-
tion, when chlamydiae were still well within their first develop-
mental cycle and when PMNs were just beginning to reach the
infected cells in the epithelium (35). The reason for this inflam-
matory difference between the virulent and attenuated variants is
not known. It could be related to the higher growth rate andmore
TABLE 5 SNPs and indels identified in variants with potential phenotype correlation relative to the Nigg genome (Genbank accession no.
AE002160)a
SNP




























58847 TC_0052: major outer membrane
protein, porin
58653 59816 C¡A G¡C C¡A G¡C
58899 TC_0052: major outer membrane
protein, porin
58653 59816 A¡ DEL A¡ DEL
58900 TC_0052: major outer membrane
protein, porin
58653 59816 A¡ DEL A¡ DEL
58901 TC_0052: major outer membrane
protein, porin
58653 59816 G¡ DEL G¡ DEL
58902 TC_0052: major outer membrane
protein, porin
58653 59816 C¡ DEL C¡ DEL
58903 TC_0052: major outer membrane
protein, porin
58653 59816 T¡ DEL T¡ DEL
59061 TC_0052: major outer membrane
protein, porin
58653 59816 T¡ DEL T¡ DEL T¡ DEL
59062 TC_0052: major outer membrane
protein, porin
58653 59816 G¡ DEL G¡ DEL G¡ DEL
59063 TC_0052: major outer membrane
protein, porin
58653 59816 T¡ DEL T¡ DEL T¡ DEL
187432 TC_0155: 3=(2=),5=-bisphosphate
nucleotidase, putative
187163 188212 G¡A H¡Y G¡A H¡Y G¡A H¡Y
187984 TC_0155: 3=(2=),5=-bisphosphate
nucleotidase, putative
187163 188212 C¡T G¡S
381736 Intergenic: NA NA NA T¡A NA¡NA
473191 TC_0412: conserved hypothetical
protein
472757 473854 ¡A FS ¡A FS
473705 TC_0412: conserved hypothetical
protein
472757 473854 G¡ FS G¡ FS G¡ FS
798169 TC_0668: conserved hypothetical
protein
797014 798240 T¡G F¡V
814976 TC_0682: tetraacyldisaccharide
4=-kinase
814899 816008 C¡A V¡L C¡A V¡L C¡A V¡L
1004276 TC_0867: conserved hypothetical
protein
1002965 1004440 T¡C S¡P T¡C S¡P T¡C S¡P T¡C S¡P
1062351 Intergenic NA NA C¡A NA¡NA C¡A NA¡NA C¡A NA¡NA
a Mutations common to all variants are excluded (see Table S1 in the supplemental material for the entire list). Chlamydial variants are arranged from highest growth rate to lowest
(left to right). Gross pathology results also followed this pattern. FS, frameshift; DEL, deletion; INS, insertion; NA, not applicable (intergenic); NT change, nucleotide change; AA
change, amino acid change.
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productive infection associated with the virulent CmVar001 vari-
ant; however, if that were the case, it would be difficult to establish
parameters to predict the possibility of different degrees of upper
genital tract pathology, especially because of dilution effects of the
population ofmultiple variants and the very strong likelihood that
individuals are infected with differing numbers of organisms.
Moreover, unlike our experimental models, women are likely ex-
posed multiple times in an ongoing relationship.
An alternative set of biomarkers is that of host miRNA differ-
entially expressed in response to infection. A recent report on
chlamydial conjunctival infection from human samples showed
differential expression of miRNAs (36). However, it did not show
any evidence of specific miRNAs in predicting pathology, as the
study compared samples from individuals with scarring and those
without inflammation in contrast to an early conjunctivitis stage
of trachoma. Our preliminary sequencing of miRNAs in mouse
cervical tissues elicited by CmVar004 and CmVar001 infections
demonstrated differential expression levels, and differences were
observed in chemokine and cytokine responses. With this evi-
dence, we then focused on the expression of 134 inflammation-
related miRNAs in order to determine if the differences seen in
chemokine and cytokine responses between the CmVar004 and
CmVar001 variants would also be reflected in specific quantitative
real-time PCR (qRT-PCR)miRNA expression profiles within 24 h
of infection. Interestingly, 12 different miRNAs (miR-135a-5p,
miR-298-5p, miR-142-5p, miR-223-3p, miR-299a-3p, miR-147-
3p, miR-105, miR-325-3p, miR-132-3p, miR-142-3p, miR155-
5p, andmiR-410-3p) were overexpressed following infection with
the attenuated variant, CmVar004, in contrast to infection with
the virulent variant, CmVar001. The results for six of these (miR-
135a-5p, miR299a-3p, miR223-3p, miR298-5p, miR142-5p, and
miR147-3p) are also statistically significant. The results with re-
spect to differential expression of miR223-3p were also supported
by the sequencing data. To our knowledge, this is the first report
demonstrating that differences in the early miRNA profile may be
predictive of the outcome of the infection with regard to upper
genital tract pathology. Because of the large number of miRNAs
with multiple regulatory functions in the immune response, it
may be possible to define a particular profile from a genital tract
specimen early in the course of infection thatwill be prognostic for
the severity of disease, allowing physicians to treat those infections
more aggressively.
The significant upregulation of 12 different miRNAs by the
attenuated variant in comparison to the virulent variant supports
our observation of a lower inflammatory chemokine and cytokine
response elicited by the avirulent variant. These results suggest
that the interaction of the attenuated variant with the host cell
initiates a pathway(s) that results in the production of miRNAs
that downregulate inflammatory responses. Conversely, the viru-
lent variant may also be initiating pathways that suppress the ex-
pression of those miRNAs, resulting in increased inflammatory
chemokine and or cytokine expression. Among those known
miRNAs that are upregulated in infection with the avirulent vari-
ant, miR-155, miR-142-3p, miR-147-3p, miR-105, and miR-132
have been shown to downregulate chemokines CXCL1, TNF-,
and IL-6 and also to modulate TLR2 expression under different
pathological conditions (15, 16, 24). We also observed a lower
CXCL1 andTNF- response in infectionwith the attenuated vari-
ant in addition to the CXCL2, CCL1, and CCL2 results noted. It is
interesting that the activation of the TLR2 pathway, in contrast to
the TLR4 pathway, is associated with the pathological response in
chlamydial genital infections (37). It is possible that activation of
certain miRNAs by the avirulent variant blocks or downregulates
the TLR2 pathway, resulting in a lower pathological response.
Nevertheless, the exact mechanism(s) by which chlamydiae initi-
ate these processes, including the role of the observed pattern of
mutations within the variant genomes, remains to be determined.
Several reports have described the role for miRNAs in regulat-
ing the chemokine and cytokine responses in bacterial induced
inflammation. For example, molecules such as lipopolysaccharide
(LPS), TNF-, and IFN- have been shown to induce miRNA
expression (26, 38, 39). DuringHelicobacter pylori infection, over-
expression ofmiR-155 reduces the expression of IL-8 and growth-
related oncogene– (GRO-) (15) in human gastric epithelial
mucosa cells. A total of 28 miRNAs are upregulated and 2 are
downregulated in patients withMycobacterium tuberculosis infec-
tion in comparison to healthy individuals. Among those, miR-
144* is possibly inhibitory for TNF- and IFN- production and
T-cell proliferation, suggesting the involvement of miRNA in an-
tituberculosis immunity (16). miR-142-3p downregulated
interleukin-1 receptor-associated kinase 1 (IRAK-1) expression,
resulting in downregulation of NF-B, TNF-, and IL-6 during
Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection in
mouse macrophages (23). In a brain inflammation model, miR-
132 was found to have an anti-inflammatory effect by targeting
mRNA of acetyl cholinesterase enzyme, which results in increased
levels of acetyl choline, an important inhibitor of peripheral in-
flammation (25). In miR-223/ mouse macrophages, signifi-
cantly elevated levels of IL-1, IL-6, and TNF- were observed in
comparison to those seenwithwild-typemacrophages during LPS
stimulation, indicating that miR-223 plays a role in anti-
inflammatory processes (22). miR-147 is induced by stimulation
of multiple TLRs, and its overexpression in mouse macrophages
decreased TNF- and IL-6 expression induced by TLR2, TLR3,
and TLR4 ligands [PAM3CSK4, poly(I · C), and LPS], indicating
that miR-147 functions in a negative-feedbackmechanism to reg-
ulate inflammation (24). In addition to this, miR-105 has also
been shown tomodulate TLR2 expression in humankeratinocytes
(21). All these reports indicate that miRNAs play a regulatory role
in chemokine and cytokine expression.
While we have presented data to demonstrate that the miRNA
profile is able to distinguish between virulent and attenuated vari-
ants in our model, the more important point is that regardless of
the specific variants, it is possible that the miRNA profile may be
able to serve as a predicative biomarker for disease severity. From
the viewpoint of humanmedicine, the nature of the actual variant
causing the disease is irrelevant; it is more important to have a
means to determine if there is an increased risk of severe outcome
so that appropriate therapy can be initiated before irreversible
pathology occurs. Moreover, the predictive value of biomarkers
such asmiRNAs early in the infection coursemay be in their use as
a measure to determine the effectiveness of a chlamydial vaccine.
Clearly, it is not feasible to use PID or infertility as an outcome for
the measure of vaccine effectiveness; rather, the miRNA profile
may have value as a correlate for PID or infertility or the lack
thereof.
In summary, we have presented evidence that an infecting
chlamydial population consists of multiple genetic variants with
distinct virulence phenotypes. Moreover, infection with virulent
versus attenuated phenotypes can be detected early in the course
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of the infection by the level of expression of specific miRNAs that
can regulate various aspects of the immune response and correlate
with the chemokine and cytokine response elicited by the variants.
Importantly, the miRNA expression profile assessed at 24 h after
infection is predictive of the eventual development of hydrosal-
pinx, the major pathological outcome for chlamydial infection in
females. While 24 h is not a practical time point to use in analyses
of human infections, the results do suggest that observable differ-
ences in themiRNA response can be detected early in the infection
course. Considering the impact of miRNAs on the regulation of
the immune response and the association of specificmiRNAswith
infection by defined chlamydial pathotypes, theymay hold prom-
ise as early-stage biomarkers to be used for prognostics in chla-
mydial genital infections.
MATERIALS AND METHODS
Cell lines. Oviduct epithelial cells (Bm1.11) were provided by Raymond
Johnson (Indiana University, Indianapolis, IN) and were cultured in
Ham’s F-12 media supplemented with 10% fetal bovine serum (FBS),
12.5 ng/ml human recombinant keratinocyte growth factor (Sigma-
Aldrich, St. Louis, MO), 2 mM GlutaMAX (Invitrogen), and 50 g/ml
gentamicin.HeLa cells andMcCoy cells were cultured inDulbecco’smod-
ified Eagle’s medium (DMEM) with 10% FBS, 1 mM glutamine, 100 M
nonessential amino acids (Invitrogen), and 50 g/ml gentamicin.
Chlamydial infection and experimental animals.Mice were infected
withC.muridarum strainNigg, which has been passaged in our laboratory
since 1977, when it was obtained from the American Type Culture Col-
lection as a yolk sac preparation. The Nigg stock, as reported by Ramsey
and coworkers, consists ofmultiple variants, some of which have the same
set of SNPs as seen in the genome sequencing of the variants obtained in
vivo in this study (K. H. Ramsey, personal communication). To obtain
chlamydial variants, nude mice were infected with 3  105 inclusion-
forming units (IFU) of C. muridarum and swabs were collected on day 6
and day 9. These swabs were plated for plaques, and random plaques were
chosen to be subjected to subplaque production and expansion.
CmVar001.1, CmVar003, and CmVar004 were collected from the day 6
swab, andCmVar002 andCmVar001 variants were collected from the day
9 swab from the same mouse. In vitro growth curve analysis was per-
formed as described previously (8) to determine the differences in growth
phenotype. Eight-week-old C57BL/6 and BALB/c mice were purchased
from Jackson Laboratories (Bar Harbor, ME) and Harlan-Sprague Daw-
ley (Indianapolis, IN), respectively. Mice were given a 2.5-mg subcutane-
ous injection of medroxyprogesterone (Depo-Provera; Upjohn, Kalama-
zoo, MI) 7 days prior to infection to place the mice in a state of anestrus.
Mice were infected intravaginally with 3 105 IFU (40) or intracervically
with 1  107 IFU as described previously (19). Cervices were collected
frommice infected intracervically for total RNA isolation 24 h after infec-
tion. To monitor the course of infection, swabs were collected frommice
infected intravaginally every 3 days for determination of IFU. On day 35,
all mice were euthanized for gross pathology observation. All protocols
were approved by the Institutional Animal Care and Use Committee at
the University of Arkansas for Medical Sciences.
Chlamydial culture. Chlamydiae were quantified from the genital
tract using a Dacro swab and then cultured in McCoy cells according to
standard procedures. In order to quantify the number of chlamydiae from
tissues, oviducts and a small portion of the upper uterine horn were dis-
sected and placed in 1 ml of 2-sucrose-phosphate buffer transport me-
dium with 0.1 mg/ml gentamicin, 0.2 mg/ml vancomycin, and 2.5 g/ml
of amphotericin B (Fungizone). The tissues were homogenized and then
sonicated for 1min. After centrifugation to pellet the large-cell debris, the
supernatants were diluted with Eagle’s minimal essential medium supple-
mented with 10% fetal bovine serum (FBS) and 5% glucose (pH 7.4) and
inoculated onto confluent HeLa cell monolayers for the determination of
IFU. Chlamydial inclusions were stained with C. muridarum-specific im-
mune serum and with a fluorescent secondary anti-mouse IgG antibody
(Alexa Fluor 488).
Genome sequencing.GenomicDNAs extracted fromplaque-purified
C. muridarum variants were subjected to library preparation and next-
generation whole-genome sequencing (paired end, 100 bp) using a single
channel of an Illumina HiSeq 2500 flow cell (1/8 channel per variant).
Sequence reads were assembled using CLC Genomics Workbench soft-
ware (version 6.0.2) by mapping reads to the C. muridarum Nigg (Gen-
bank accession no. AE002160) reference genome (similarity fraction 
0.85) (41) (see Table S1). For each sequenced isolate, consensus contigs
were extracted and ordered into a pseudomolecule, using the reference
genome for contig order. Gene identification and annotation were per-
formed as previously described (42). SNPs and indels between C. muri-
darum variants and the referenceC.muridarum genomewere identified as
previously described using aNUCmer-based bioinformatics pipeline (43–
45).
Total RNA isolation and expression analysis of miRNA and mRNA
transcripts. Total RNA was isolated from cervices and cell samples by
using anmiRNeasy kit (Qiagen) after 24 h of infection with CmVar004 or
CmVar001. Animals in a control group were sham inoculated. The con-
centration of RNA was determined by Nanodrop, and absorbance at 260
and 280 and absorbance at 260 and 230 were taken into consideration to
check for RNA quality. RNA was reverse transcribed with SuperScript III
enzyme (Invitrogen) according to the manufacturer’s instructions using
random hexamer and dT for priming. Quantitative PCR was performed
on samples using IQ-SYBR mix (Bio-Rad) and a CFX96 PCR detection
system (Bio-Rad). Levels of chlamydial rRNA (rs16) were measured to
determine chlamydial growth, and samples that showed rs16 levels similar
to those determined for CmVar004 and CmVar001 were chosen for
chemokine and cytokine (9 individual animals per [control, CmVar004,
or CmVar001] group) analyses and miRNA analyses (4 to 5/group). All
primers were designed using Beacon Design software (Bio-Rad).
To analyzemiRNAs by sequencing, total RNAs of 4 samples from each
group were subjected to small-RNA sequencing. To analyze miRNA by
sequencing, total RNAwas size selected and sequenced. Total RNAquality
was assessed using an RNA Nano chip on an Agilent BioAnalyzer 2100
instrument (Agilent Technologies) prior to library preparation. Sequenc-
ing libraries were constructed using a DGE Small RNA Library Prepara-
tion kit (Illumina). Library preparations were validated by the use of a
BioAnalyzer 2100 system using High Sensitivity DNA chips (Agilent
Technologies) prior to sequencing. Small-RNA sequencing was per-
formed using an Illumina MiSeq instrument. miRNAs were mapped to
the mouse reference genome (GRCm38.70) using Bow tie v 0.12.9 (max-
imum number of mismatches  2) (46). The number of reads mapped
to each miRNA was counted by HTSeq against the annotated mouse
miRNA gff3 file downloaded from miRBase (release 20) (47). Data nor-
malization and differential gene expression analyses were performed us-
ing DESeq (48) and EdgeR (49), independently comparingC. muridarum
CmVar004-infected and CmVar001-infected replicates to uninfected
controls. Up- and downregulated miRNAs were filtered for significantly
differentially expressed miRNAs using the following parameters: a cutoff
false-discovery rate (FDR)0.05;minimum read count 10; an upper
fold change value of 1; and a lower fold change value of 1. To confirm
the miRNA sequencing results and also to focus on immune-related
miRNAs, we measured miRNA expression levels for 5 samples per group
to run miRNA arrays from Qiagen that contained 134 different miRNAs
related to inflammation (combination of inflammatory response and au-
toimmunity and immunopathogenesis miScript miRNA PCR arrays).
Data analyses were performed using Web-based software provided by
SABiosciences. miRNA expression analyses were performed during
CmVar004 and CmVar001 infection with respect to control animals, and
small nucleolar RNAs (SNORDs) were also used as internal controls
(SNORD 61, 68, 72, 95, and 96A), which had the least variability of all the
samples with respect to CmVar004 and CmVar001 infection. Data are
presented as a clustergram and indicate fold change differences in regula-
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tion (up or down) of miRNAs. Data obtained by comparisons to the
control were used to determine the fold change differences between
CmVar004 and CmVar001 with respect to expression of individual
miRNAs by using the one-tailed t test.
Statistical analysis. Data are presented as the mean  1 standard
deviation. The course of the infection among variants was analyzed with a
2-factor (days, group) analysis of variance with repeatedmeasures. Statis-
tical analyses for chemokine and cytokine data were carried out only with
the measurements that showed a higher fold increase with the CmVar001
variant than with the CmVar004 variant, and data were analyzed by one-
tailed t test. MicroRNAs that showed fold increases in mice that were
infected with CmVar004 in comparison to those infected with CmVar001
were analyzed for statistical significance by a nonparametric one-tailed
(with Bonferroni correction) Wilcoxon rank sum test.
Nucleotide sequence accession numbers. The whole genome shot-
gun project has been deposited atDDBJ/EMBL/GenBank under accession
numbers JNON00000000, JNOO00000000, JNOP00000000,
JNOQ00000000, and JNOR00000000.
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